title: [Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in neonates and young infants].
abstract: Twenty three neonates and young infants were treated with imipenem/cilastatin sodium (IPM/CS) and its clinical efficacy and side effects were evaluated. Ages of the patients ranged from 0 to 83 days, and their body weights ranged from 750 to 4,760 g. Doses of IPM/CS ranged from 17.4 to 21.5 mg/kg as IPM every 6 to 12 hours for 3 to 12 days. Sixteen patients with infections including sepsis, meningitis and pneumonia, appeared to have responded to the IPM/CS treatment. Among them, clinical results were excellent in 2, good in 12 and fair in 2 patients. The drug was well tolerated, but 1 patient had diarrhea, 1 had redness of body during infusion, 1 had elevated GOT and GPT, and 2 patients showed only elevated values of GOT only among the 23 patients. The pharmacokinetics of IPM/CS were studied in 7 patients. Their ages ranged from 0 to 9 days, and body weights ranged from 2.5 to 4.0 kg. Serum concentrations of IPM were between 18.0 and 96.9 micrograms/ml and those of CS ranged 31.7 and 144.5 micrograms/ml in 6 patients at the end of intravenous drip infusion 20 mg/20 mg/kg during 30 or 60 minutes. Elimination half-lives of IPM ranged from 1.2 to 2.0 hours, and those of CS ranged from 1.4 to 2.7 hours. Serum concentrations of IPM was 14.7 micrograms/ml and that of CS was 32.4 micrograms/ml in 1 patient at the end of 30 minute-drip infusion 10 mg/10 mg/kg. The elimination half-lives of IPM was 1.5 hours, and that of CS was 2.9 hours.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Pediatrics, Asahikawa Medical College.
authors.forename: H
authors.initials: H
authors.lastname: Sakata
authors.forename: H
authors.initials: H
authors.lastname: Kakehashi
authors.forename: K
authors.initials: K
authors.lastname: Fujita
authors.forename: K
authors.initials: K
authors.lastname: Murono
authors.forename: M
authors.initials: M
authors.lastname: Kaeriyama
authors.forename: T
authors.initials: T
authors.lastname: Oka
authors.forename: H
authors.initials: H
authors.lastname: Yoshioka
authors.forename: N
authors.initials: N
authors.lastname: Sasaki
authors.forename: Y
authors.initials: Y
authors.lastname: Mori
authors.forename: S
authors.initials: S
authors.lastname: Maruyama
mesh_terms: D001424:Bacterial Infections / Q000097:blood / Q000188:drug therapy* / Q000652:urine; D015377:Cilastatin / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D005260:Female; D006207:Half-Life; D006801:Humans; D015378:Imipenem / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D007223:Infant; D007231:Infant, Newborn; D007262:Infusions, Intravenous; D008297:Male; D008581:Meningitis / Q000097:blood / Q000134:cerebrospinal fluid / Q000188:drug therapy
chemical_list: D015377:Cilastatin; D015378:Imipenem